Medcolcanna expands Global Leadership Team with Appointment of Chief Corporate Development Officer
22 November 2019 - 8:30AM
Medcolcanna Organics Inc. (TSX-V: MCCN)
(“
Medcolcanna” or the “
Company”)
announces the expansion of its senior leadership team with the
appointment of Daniel Herrera as Chief Corporate Development
Officer. Daniel will lead Medcolcanna’s corporate development
function, including the global export market sales development,
Global Partnerships and strategic corporate investments. Pursuant
his employment agreement executed on November 19, 2019, and subject
to applicable regulatory and stock exchange approvals, he will be
issued shares in the capital of the Company, at a deemed price of
the closing price of the shares of the Company on that date.
Daniel was previously with CannTrust Holdings
Inc., where he was Director of Global Strategy and Business
Development also serving as lead of the Global Partnerships and
Investments group, where he advised on several M&A and sales
transactions in Denmark, Germany, Australia and the US, including
acquisition and licensing of technologies related to the cannabis
and biopharmaceutical sector.
Daniel comes to Medcolcanna with over 15 years’
experience in the pharmaceutical industry serving in various
commercial and strategic roles at Eli Lilly and Company. Daniel is
a graduate of McGill University, the University of Montreal and
earned an MBA from the John Molson School of Business at Concordia
University.
Felipe De La Vega, Medcolcanna’s CEO, said, “We
are pleased to welcome Daniel to our senior leadership team to
accelerate export sales from Colombia, enhance strategic
partnerships and potential transactions that will further
accelerate Medcolcanna’s long-term global growth. Daniel shares our
company’s commitment to a disciplined, strategic approach in
pursuing growth opportunities. His cannabis and pharmaceutical
industry experience and knowledge will be valuable as we work to
capitalize on the many strategic opportunities available to us and
continue to pursue the disruptive potential of cannabis across
industries including pharmaceuticals, alcohol, consumer goods,
functional food and beverage, retail, nutraceutical and
veterinary.”
ABOUT MEDCOLCANNA Medcolcanna
is a Canadian integrated medical cannabis company, whose fully
licensed operations are based in Colombia. Led by a proven and
successful management team, Medcolcanna has facilities in optimal
growing locations which positions the Company to become a global
leader in the medical cannabis market.
Medcolcanna employs state of the art organic
agricultural technology and innovative pharmaceutical processes to
produce high-quality products. The Company’s scalable production
model and network of pharmaceutical partnerships globally ensures
that they remain at the forefront of the medical cannabis
industry.
If you would like to receive News Releases via
e-mail as soon as they are published, please subscribe here:
https://medcolcanna.com/contact-us/
Additional information about Medcolcanna can be
found on its web site at www.medcolcanna.com
Neither the TSX Venture Exchange Inc. nor
its regulation services provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release and neither of these
entities has in any manner passed upon the merits of the
Transaction or any associated
transactions.
Medcolcanna Investor Relations
Contact:Chris Reid, CFOCarrera 49b # 93-62Bogotá,
ColombiaPhone: +571 642-9113Email: info@medcolcanna.com
Juan José Arango, Marketing DirectorCarrera 49b
# 93-62Bogotá, ColombiaPhone: +571 642-9113Email:
info@medcolcanna.com
This news release contains “forward-looking
information” and “forward-looking statements” (collectively,
“forward-looking statements”) within the meaning
of the applicable Canadian securities legislation. All statements,
other than statements of historical fact, are forward-looking
statements and are based on expectations, estimates and projections
as at the date of this news release. Any statement that involves
discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, assumptions, future events or
performance (often but not always using phrases such as “expects”,
or “does not expect”, “is expected”, “anticipates” or “does not
anticipate”, “plans”, “budget”, “scheduled”, “forecasts”,
“estimates”, “believes” or “intends” or variations of such words
and phrases or stating that certain actions, events or results
“may” or “could”, “would”, “might” or “will” be taken to occur or
be achieved) are not statements of historical fact and may be
forward-looking statements. Forward-looking statements are
necessarily based upon a number of estimates and assumptions that,
while considered reasonable, are subject to known and unknown
risks, uncertainties, and other factors which may cause the actual
results and future events to differ materially from those expressed
or implied by such forward-looking statements. Such factors
include, but are not limited to general business, economic,
competitive, political and social uncertainties; and the delay or
failure to receive board, shareholder or regulatory approvals.
There can be no assurance that such statements will prove to be
accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on the forward-looking
statements and information contained in this news release.
Medcolcanna assumes no obligation to update the
forward-looking statements of beliefs, opinions, projections, or
other factors, should they change, except as required by law.
Medcolcanna Organics (TSXV:MCCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medcolcanna Organics (TSXV:MCCN)
Historical Stock Chart
From Jul 2023 to Jul 2024